Successful treatment of severe pneumocystis pneumonia with clindamycin-primaquine in an HIV-negative patient.
Pneumocystis pneumonia is an increasingly recognized threat in non-HIV immunosuppressed patients and is associated with worse outcomes compared to HIV-infected patients. The preferred first line treatment is trimethoprim-sulfamethoxazole; however, second line treatments for those intolerant of this regimen have been primarily studied in patients with acquired immunodeficiency syndrome (AIDS). We report a case of Pneumocystis pneumonia in a 75-year-old man with chronic lymphocytic leukemia (CLL) and a history of sulfa allergy successfully treated with clindamycin-primaquine.
Department of Internal Medicine, Wilford Hall Medical Center, Lackland AFB, TX, USA.
Howard C
HC
Crisp
Ian J
IJ
Stewart
Peter J
PJ
Blatz
David H
DH
Rice
Jason F
JF
Okulicz
D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D018023:HIV Seronegativity; D006801:Humans; D008297:Male; D045363:Pneumocystis carinii / Q000187:drug effects; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D011319:Primaquine / Q000627:therapeutic use*
D000935:Antifungal Agents; D002981:Clindamycin; D011319:Primaquine